A major scandal has erupted at Dalal Jamm hospital in Senegal, exposing a network of medication resale that has left patients vulnerable to exorbitant costs. The scheme was uncovered on September 22, 2025, when an individual, J. M. Faye, arrived at the hospital pharmacy with 300 ampoules of Midazolam, a powerful sedative. The medication, set to expire in October 2025, was offered to the hospital in exchange for other commercially viable drugs.
The proposed deal, allegedly approved by the hospital's director, Dr. Samba Guèye, was met with resistance from Professor Fall, the head of the service. Fall rejected the offer, citing public acquisition regulations, and had the medication placed under provisional custody. However, on September 26, 2025, the medication mysteriously disappeared from the Cellule de passation des marchés, where it was being stored, and was returned to Faye.
The disappearance of the medication has raised serious concerns about the potential for it to be sold on the black market or used in clandestine clinics. Midazolam requires strict control over its traceability and conservation, and administering it without guarantee of origin poses significant risks to patients. Professor Fall has been vocal about the scandal, informing the director general of the Agence de réglementation pharmaceutique, Aliou Abou Talib Diouf, and filing official complaints with the Ordre des pharmaciens and the Syndicat.
Fall's complaints also included a request for the monitoring of phone conversations between Faye, the contract pharmacist, and the hospital management. The case has been under investigation by the DIC, but Professor Fall has observed a lack of progress over the past year. The scandal has gained momentum amid a politically charged atmosphere, with opposition deputy Guy Marius Sagna raising concerns about the porosity of hospital supply chains.
Sagna has been questioning the Minister of Health through written inquiries and direct interventions during parliamentary investigation commissions, but has yet to receive a response. The lack of action from state authorities has raised concerns about the extent of the problem and the potential for similar scandals to occur.
The Dalal Jamm hospital scandal highlights the need for greater oversight and regulation in the healthcare sector. The case has sparked widespread concern and outrage, with many calling for swift action to be taken against those involved. As the investigation continues, it remains to be seen what consequences those responsible will face.
The incident has also raised questions about the broader implications for the healthcare system in Senegal. With many patients relying on the hospital for life-saving medication, the scandal has exposed weaknesses in the system that must be addressed. As the situation unfolds, one thing is clear: the people of Senegal deserve a healthcare system that prioritizes their well-being and safety.
Key points
- A major medication trafficking network has been uncovered at Dalal Jamm hospital in Senegal.
- The scandal involves the resale of 300 ampoules of Midazolam, a powerful sedative, on the black market.
- The case has sparked widespread concern and outrage, with many calling for swift action to be taken against those involved.
